Why the study?
Do (-)-epigallocatechin gallate (EGCG), quercetin, and resveratrol alter NADPH-cytochrome P-450 reductase activity in human heart, liver, and lung microsomes?
Do (-)-epigallocatechin gallate (EGCG), quercetin, and resveratrol alter NADPH-cytochrome P-450 reductase activity in human heart, liver, and lung microsomes?
Dietary quercetin and EGCG enhance P-450 reductase activity in vitro, which may increase the risk of doxorubicin-induced toxicity.
Quercetin or EGCG may raise doxorubicin toxicity risk; animal data leave human relevance open and hypothesis-generating.
NADPH-cytochrome P-450 reductase (P-450 reductase) plays a crucial role in the metabolism of many endogenic compounds and xenobiotics detoxication. The enzyme is also involved in the toxicity of some clinically important antitumour drugs (doxorubicin) and pesticides (paraquat). P-450 reductase activates them to their more toxic metabolites via one electron reduction which triggers free radical cascade. In some cases however, such transformation is essential to produce therapeutic effect in anticancer drugs. The main purpose of the paper was to evaluate the effect of three natural compounds found in human diet: (-)-epigallocatechin gallate (EGCG), quercetin and resveratrol on P-450 reductase activity. The activity of the enzyme was determined spectrophotometrically by measurement of the rate of cytochrome c reduction at 550 nm, in vitro, using human heart, liver and lung microsomes. It was found that quercetin increased the P-450 reductase activity in human organs at all tested doses. The activity of microcosms in all organs was enhanced according to the concentrations of quercetin, which increased the activity in the order lung>heart>liver. Addition of EGCG to the reaction mixture enhanced the P-450 reductase activity in the following order: liver>heart>lung. However, no significant effect of resveratrol on P-450 reductase activity was observed. It seems that the presence of quercetin and EGCG in the diet may increase P-450 reductase activity during doxorubicin therapy with subsequent increased risk of toxicity. A beneficial effect may be obtained in anticancer therapy with bioreductive agents like tirapazamine.
No takes yet. Share an insight, caveat, or question.
Dudka et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: